Addition of dexmedetomidine to benzodiazepines for patients with alcohol withdrawal syndrome in the intensive care unit: a randomized controlled study

BACKGROUND: Dexmedetomidine (DEX) is a centrally acting alpha-2-adrenoceptor agonist that has potential in the management of alcohol withdrawal syndrome (AWS) owing to its ability to produce arousable sedation and to inhibit the adrenergic system without respiratory depression. The objective of this...

Descripción completa

Detalles Bibliográficos
Autores principales: Bielka, Kateryna, Kuchyn, Iurii, Glumcher, Felix
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Paris 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4630264/
https://www.ncbi.nlm.nih.gov/pubmed/26525052
http://dx.doi.org/10.1186/s13613-015-0075-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4630264/
https://www.ncbi.nlm.nih.gov/pubmed/26525052
http://dx.doi.org/10.1186/s13613-015-0075-7

Ejemplares similares